Silexion Therapeutics Corp (SLXN): Total Assets
$7.21M
As of 2025-12-31
$4.25M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.21M | +152.0% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $2.86M | -45.5% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $5.26M | n/a | 2025-03-18, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | 2025-12-31 | $7.21M | +152.0% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $7.39M | -49.6% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $7.81M | +17.1% |
| Exozymes Inc. (EXOZ) | 2025-12-31 | $5.97M | -54.2% |
| Calidi Biotherapeutics, Inc. (CLDI) | 2025-12-31 | $8.86M | -37.5% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $5.78M | -32.8% |
| Greenland Mines Ltd (GRML) | 2025-12-31 | $9.59M | +290.4% |
| Eloxx Pharmaceuticals, Inc. (ELOX) | 2025-12-31 | $5.27M | +77.1% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $9.95M | +0.2% |
Compare SLXN, VIVS, CELZ, EXOZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗